EIC helps Trailhead Biosystems secure $6.6 million Series A financing

We are thrilled to have provided critical support in closing a $6.6 million round of Series A financing to Trailhead Biosystems Inc.

Trailhead aims to rapidly develop the capability of creating specialized human cells at high purity for regenerative medicine and therapeutic purposes at an industrial scale.

Trailhead develops products that target Type 1 diabetes, neurodegenerative diseases, including Parkinson’s disease, multiple sclerosis, and Alzheimer’s disease, heart failure, and blood disorders. Its proprietary and versatile HD-DoE (High-Dimensional Design of Experiments) platform allows it to perform systems-level interrogation of various complex biological problems, ranging from the generation of industrially-scalable manufacturing conditions for specialized human cells to combinatorial drug discovery in cancer and anti-viral therapies.

A team of Yale Law students took the lead in advising Trailhead on its Series A financing, including drafting the transaction agreements, under the supervision of Prof. Sven Riethmueller, Clinical Associate Professor of Law at Yale Law School and the inaugural Director of the Entrepreneurship & Innovation Clinic at Yale Law School.